(Q38743781)

6 September 2017

title

The Effect of Molecular Diagnostics on the Treatment of Glioma (English)

1 reference

6 September 2017

author

Nancy Ann Oberheim Bush

series ordinal

1

object named as

Nancy Ann Oberheim Bush

1 reference

6 September 2017

Nicholas Butowski

2

1 reference

6 September 2017

publication date

1 April 2017

1 reference

6 September 2017

published in

Current Oncology Reports

1 reference

6 September 2017

volume

19

1 reference

6 September 2017

issue

4

1 reference

6 September 2017

page(s)

26

1 reference

The 2007 WHO classification of tumours of the central nervous system

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Histologic classification of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

MGMT testing--the challenges for biomarker-based glioma treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Predictive impact of MGMT promoter methylation in glioblastoma of the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

The somatic genomic landscape of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Recent Advances on the Molecular Pathology of Glial Neoplasms in Children and Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Epidermal growth factor receptor targeting and challenges in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

IDH mutation impairs histone demethylation and results in a block to cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Cancer: Oncogene brought into the loop.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Topological domains in mammalian genomes identified by analysis of chromatin interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Insulator dysfunction and oncogene activation in IDH mutant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Interlaboratory comparison of IDH mutation detection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

A vaccine targeting mutant IDH1 induces antitumour immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Mutations in CIC and FUBP1 contribute to human oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Novel CIC point mutations and an exon-spanning, homozygous deletion identified in oligodendroglial tumors by a comprehensive genomic approach including transcriptome sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Telomere maintenance and the etiology of adult glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Altered telomeres in tumors with ATRX and DAXX mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Further understanding of the pathology of glioma: implications for the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Genetic Analysis of Diffuse High-Grade Astrocytomas in Infancy Defines a Novel Molecular Entity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Rapid Intraoperative Molecular Characterization of Glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

BRAF(V600E) mutation is a negative prognosticator in pediatric ganglioglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Targeted therapy for BRAFV600E malignant astrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

EGFR blockade prevents glioma escape from BRAFV600E targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Toward precision medicine in glioblastoma: the promise and the challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0585-6

Definition of limits and 3D configuration of cerebral gliomas. Histological data, therapeutic incidences (author's transl)

21 January 2018

1 reference

12 December 2020

IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis

1 reference

12 December 2020

The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas

1 reference

12 December 2020

MGMT immunohistochemical expression and promoter methylation in human glioblastoma

1 reference

12 December 2020

Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis.

1 reference

12 December 2020

BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.

1 reference

12 December 2020

Acquired resistance to BRAF inhibition in BRAFV600E mutant gliomas

1 reference

12 December 2020

10.1007/S11912-017-0585-6

Identifiers

DOI

1 reference

Dimensions Publication ID

6 September 2017

1084033431

0 references

1 reference